A CRISPR-Cas9 Generated MDCK Cell Line Expressing Human MDR1 Without Endogenous Canine MDR1 (cABCB1): An Improved Tool for Drug Efflux Studies.
暂无分享,去创建一个
Maria Backlund | Per Artursson | Maria Karlgren | Christine Wegler | Stefan Oswald | P. Artursson | C. Wegler | S. Oswald | Ivailo Simoff | Markus Keiser | Niklas Handin | Janett Müller | Patrik Lundquist | Anne-Christine Jareborg | N. Handin | Janett Müller | M. Keiser | M. Backlund | P. Lundquist | I. Simoff | M. Karlgren | Anne-Christine Jareborg
[1] Karen Methling,et al. Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1. , 2015, British journal of clinical pharmacology.
[2] Ying Wang,et al. Kinetic analysis of human and canine P-glycoprotein-mediated drug transport in MDR1-MDCK cell model: approaches to reduce false-negative substrate classification. , 2013, Journal of pharmaceutical sciences.
[3] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[4] J. Polli,et al. Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.
[5] B. Rothen‐Rutishauser,et al. P-Glycoprotein in cell cultures: a combined approach to study expression, localisation, and functionality in the confocal microscope. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[6] J. Dukes,et al. The MDCK variety pack: choosing the right strain , 2011, BMC Cell Biology.
[7] M. Niemi,et al. Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.
[8] L Zhang,et al. Transporter Studies in Drug Development: Experience to Date and Follow‐Up on Decision Trees From the International Transporter Consortium , 2013, Clinical pharmacology and therapeutics.
[9] P. Verhoest,et al. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. , 2010, ACS chemical neuroscience.
[10] J. König,et al. Double‐transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations , 2011, British journal of pharmacology.
[11] I. Hidalgo,et al. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. , 2005, International journal of pharmaceutics.
[12] P. Artursson,et al. In Vitro Characterization of Interactions with Drug Transporting Proteins , 2013 .
[13] T. Celius,et al. Stable suppression of MDR1 gene expression and function by RNAi in Caco-2 cells. , 2004, Biochemical and biophysical research communications.
[14] P. Borst,et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[15] J. Donovan,et al. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein , 2006, Psychopharmacology.
[16] T. Abe,et al. Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)* , 2002, The Journal of Biological Chemistry.
[17] M. Gottesman,et al. Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.
[18] G. Fricker,et al. Establishment of optimized MDCK cell lines for reliable efflux transport studies. , 2014, Journal of pharmaceutical sciences.
[19] Li Di,et al. Development of a new permeability assay using low-efflux MDCKII cells. , 2011, Journal of pharmaceutical sciences.
[20] Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases , 2015, Pharmaceutical Research.
[21] D. Keppler,et al. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. , 2001, Molecular pharmacology.
[22] Tudor I. Oprea,et al. Improving the prediction of the brain disposition for orally administered drugs using BDDCS. , 2012, Advanced drug delivery reviews.
[23] Wolfgang Löscher,et al. Differences in the expression of endogenous efflux transporters in MDR1‐transfected versus wildtype cell lines affect P‐glycoprotein mediated drug transport , 2010, British journal of pharmacology.
[24] I. Pastan,et al. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[25] Yong Li,et al. Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing. , 2016, American journal of translational research.
[26] G. M. Pollack,et al. Kinetic Considerations for the Quantitative Assessment of Efflux Activity and Inhibition: Implications for Understanding and Predicting the Effects of Efflux Inhibition , 2007, Pharmaceutical Research.
[27] T. Iwatsubo,et al. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood–brain barrier , 2012, Biopharmaceutics & drug disposition.
[28] Maria Backlund,et al. Complete Knockout of Endogenous Mdr1 (Abcb1) in MDCK Cells by CRISPR-Cas9. , 2016, Journal of pharmaceutical sciences.
[29] J. Markowitz,et al. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. , 2002, Life sciences.